houthakker
Advanced Bodybuilder
- Lid sinds
- 24 nov 2004
- Berichten
- 1.326
- Waardering
- 34
- Lengte
- 1m88
- Massa
- 91kg
- Vetpercentage
- 15%
middellange prestaties
- Topic starter houthakker
- Startdatum
- Recente activiteit Recente activiteit:
- Reacties 10
- Weergaven 2.455
- Volgers 0
gerardus
Cool Novice
- Lid sinds
- 24 mrt 2004
- Berichten
- 133
- Waardering
- 0
- Lengte
- 1m72
- Massa
- 88kg
- Vetpercentage
- 9%
haazebr
Advanced Bodybuilder
- Lid sinds
- 14 mrt 2003
- Berichten
- 1.046
- Waardering
- 2
- Lid sinds
- 15 nov 2002
- Berichten
- 50.099
- Waardering
- 2.658
- Lengte
- 1m79
- Massa
- 96kg
- Vetpercentage
- 21%
Met creatine verzuur je net zoveel of weinig als je lichaam aankan, je verzuringsgrens (omslagpunt) wordt er niet door beinvloed. Je hebt wel een iets langere ATP-verbranding, in die zin verzuur je misschien iets later maar dan praat je alleen over de eerste explosieve seconden om weg te komen. Voor sprinten en achtervolging kan creatine dus zeker baten. Ik had er zelfs baat bij toen ik normale wielertraining deed, beter herstel en meer punch in mijn sprint.
houthakker
Advanced Bodybuilder
- Lid sinds
- 24 nov 2004
- Berichten
- 1.326
- Waardering
- 34
- Lengte
- 1m88
- Massa
- 91kg
- Vetpercentage
- 15%
- Lid sinds
- 12 nov 2002
- Berichten
- 1.035
- Waardering
- 1
houthakker zei:
Kijk voor aas even in de stickies, daar vindt je voorlopig genoeg.
Nesp, oftewel Aranesp (ook wel darbepoetin) is dus wel te vinden in de markt maar ook op te sporen door dopingjagers, vraag maar aan Johan Muelegg die zijn olympische plak kwijt raakte. Mocht je hier toch voor kiezen, let dan vooral goed op je ijzerinname. Perftoran of Fluosol zijn ook mogelijkheden om de zuurstofopname te verbeteren, het zijn eigenlijk bloedplasmavervangers maar moeilijker verkrijgbaar.
Maar als ik jou zo hoor zou ik het eerst effe lekker bij een potje creatine houden en goed naar voeding blijven kijken. AS nog zeker maar laten voor wat het is, om van de bovenstaande middelen nog maar te zwijgen. Als je niet in staat bent om regelmatig je hematocrietwaarde te bepalen, dan moet je er echt afblijven.
- Lid sinds
- 15 nov 2002
- Berichten
- 50.099
- Waardering
- 2.658
- Lengte
- 1m79
- Massa
- 96kg
- Vetpercentage
- 21%
houthakker
Advanced Bodybuilder
- Lid sinds
- 24 nov 2004
- Berichten
- 1.326
- Waardering
- 34
- Lengte
- 1m88
- Massa
- 91kg
- Vetpercentage
- 15%
- Lid sinds
- 12 nov 2002
- Berichten
- 1.035
- Waardering
- 1
FF googlen.........
Pharmacology Update: Perftoran – Perfluorocarbon-Based Oxygen Carrier
Perftoran is both a product and a company name. The company was formed in 1997 by the Ministry of Public Health and Medical Institute of Russian Federation. Perftoran is a perfluorocarbon-based oxygen carrier (PBOC), consisting of perfluorodecalin, perfluoromethylcyclohexylpiperidine and proxanol. Perftoran is similar to Fluosol®, the first PBOC to be used in the late 1970’s, with the exception that the emulsifier is new and improved. Fluosol® was associated with several problems, including cumbersome preparation procedures, side-effects and modest oxygen transport characteristics. However, the incidence of side-effects associated with Perftoran is considerably lower; this is probably related to the emulsifier (less complement activation). Perftoran has a small particle size, i.e. 0.07 mm. Smaller particles evade the reticuloendothelial system more easily, which results in longer intravascular persistence and lesser side-effects. In addition, smaller particles traverse the microcirculation with less resistance.
Perftoran is marketed as "a multipurpose substance able to correct various type of hypoxia." Several clinical studies have been conducted using Perftoran in patients undergoing neurosurgery for cranial trauma and kidney transplantation, revealing improved morbidity and mortality. 757 wounded and critically ill patients were treated with Perftoran. The indications included hypovolemia, DIC, bronchopulmonary lavage, regional perfusion of extremities, to mention a few. Results were compared to a control group of 976 patients. Perftoran performed extremely well as an oxygen transport medium. Hemodynamic function improved in hypovolemic patients while hepatic function recovery was accelerated. The need for allogeneic blood decreased, while the incidence of ARDS was less in patients treated with Perftoran. Perftoran was also used during cardiac surgery as a blood substitute during cardiopulmonary bypass and in cardioplegic solutions. The results were similarly impressive - decreased hemolysis of red blood cells, rapid restoration of cardiac activity.
These dramatic results are attributed to a variety of responses that are related to not only improved gas transport, but also blood viscosity and cellular membrane function. Perftoran must be stored frozen and has a shelf-life of 2 years. It may be thawed and refrozen 5 times. As a "new and improved" first-generation PBOC, these initial results suggest that Perftoran has considerable clinical efficacy in a variety of settings. However, Perftoran has not been used in conjunction with ANH. Its potential application to this technique is an important question that will require additional research. It is uncertain whether Perftoran will be available on a worldwide basis – the company maintains a web site at [Link niet meer beschikbaar].
Pharmacology Update: Perftoran – Perfluorocarbon-Based Oxygen Carrier
Perftoran is both a product and a company name. The company was formed in 1997 by the Ministry of Public Health and Medical Institute of Russian Federation. Perftoran is a perfluorocarbon-based oxygen carrier (PBOC), consisting of perfluorodecalin, perfluoromethylcyclohexylpiperidine and proxanol. Perftoran is similar to Fluosol®, the first PBOC to be used in the late 1970’s, with the exception that the emulsifier is new and improved. Fluosol® was associated with several problems, including cumbersome preparation procedures, side-effects and modest oxygen transport characteristics. However, the incidence of side-effects associated with Perftoran is considerably lower; this is probably related to the emulsifier (less complement activation). Perftoran has a small particle size, i.e. 0.07 mm. Smaller particles evade the reticuloendothelial system more easily, which results in longer intravascular persistence and lesser side-effects. In addition, smaller particles traverse the microcirculation with less resistance.
Perftoran is marketed as "a multipurpose substance able to correct various type of hypoxia." Several clinical studies have been conducted using Perftoran in patients undergoing neurosurgery for cranial trauma and kidney transplantation, revealing improved morbidity and mortality. 757 wounded and critically ill patients were treated with Perftoran. The indications included hypovolemia, DIC, bronchopulmonary lavage, regional perfusion of extremities, to mention a few. Results were compared to a control group of 976 patients. Perftoran performed extremely well as an oxygen transport medium. Hemodynamic function improved in hypovolemic patients while hepatic function recovery was accelerated. The need for allogeneic blood decreased, while the incidence of ARDS was less in patients treated with Perftoran. Perftoran was also used during cardiac surgery as a blood substitute during cardiopulmonary bypass and in cardioplegic solutions. The results were similarly impressive - decreased hemolysis of red blood cells, rapid restoration of cardiac activity.
These dramatic results are attributed to a variety of responses that are related to not only improved gas transport, but also blood viscosity and cellular membrane function. Perftoran must be stored frozen and has a shelf-life of 2 years. It may be thawed and refrozen 5 times. As a "new and improved" first-generation PBOC, these initial results suggest that Perftoran has considerable clinical efficacy in a variety of settings. However, Perftoran has not been used in conjunction with ANH. Its potential application to this technique is an important question that will require additional research. It is uncertain whether Perftoran will be available on a worldwide basis – the company maintains a web site at [Link niet meer beschikbaar].